The U.S. pays steep prices for brand-name drugs, but generics—responsible for about nine of every 10 prescriptions—have kept many medicines affordable. That balance is at risk depending on the Supreme Court’s decision in Hikma v. Amarin, a case that centers on a key tactic generics use to reach market sooner: skinny labeling.
Skinny labeling lets a generic firm obtain FDA approval for only the noninfringing uses of a drug, deliberately excluding patented indications. By selling versions limited to those permitted uses, companies often avoid protracted patent fights and can deliver lower-cost alternatives to patients and insurers earlier. More than two dozen generics have used this approach in the past decade; one study estimated skinny labeling saved Medicare nearly $15 billion from 2015 to 2021.
The dispute began when Hikma introduced a generic version of Amarin’s Vascepa, a purified fish-oil product, in 2020 with a skinny label after some Vascepa patents lapsed. Amarin sued, accusing Hikma of encouraging doctors to prescribe the generic for a still-patented use as well as the unpatented indication. Amarin pointed to marketing language and other conduct it said facilitated off-label prescribing for the patented group. A federal appeals court sided with Amarin, and Hikma asked the Supreme Court to review that decision.
Supporters of Hikma—including more than 70 legal scholars and the U.S. solicitor general—argue that ordinary marketing and factual product descriptions should not expose generics to sweeping patent liability. They contend that if routine labeling and neutral promotional practices can be treated as inducement to infringe, the skinny-label pathway will be impractical. That, in turn, could discourage early generic entry and keep prices higher for longer.
If the Court rules for Amarin, experts warn, generic manufacturers might avoid skinny labels to reduce litigation risk, opting instead for slower strategies such as waiting for all patents to expire or pursuing alternatives that invite their own legal challenges. Such delays can extend brand monopolies; for example, skinny labeling allowed competition for Crestor to begin years earlier than it otherwise might have, generating big savings in the first year of generic entry.
Other commentators urge caution about worst-case predictions. Even if the risk of suits increases, skinny labeling could remain commercially attractive, and some manufacturers may view litigation costs as an acceptable expense for faster market access. If the Court sides with Hikma, the legal status quo largely remains, and immediate impacts on price would likely be limited.
The case raises a broader policy question: how to balance incentives for brand companies to invest in new, patented indications against the public interest in quick, low-cost access to generics. Observers note signs favoring Hikma—the solicitor general’s backing, the Supreme Court’s record of reversing lower courts, and recent decisions making inducement harder to prove—but the ruling could range from a narrow decision that preserves existing law to a broad one that significantly shields or restricts skinny-label practices.
More than a single fish-oil drug is at stake. The Supreme Court’s outcome will shape the legal and commercial landscape for generic competition and influence how quickly patients and payers gain access to lower-cost medicines.